Author

Xinpei Yu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Osimertinib plus anlotinib shows promising efficacy and manageable toxicity as first-line treatment for advanced NSCLC with EGFR co-mutations.

Xiao-Jun Yang, Qin-Quan Tan, Shi-Yuan Chen et al. · The Oncologist · 0 citations